Managing blood pressure and using dexamethasone during lung cancer surgery
Impact of Intraoperative Blood Pressure Management and Dexamethasone on Patient's Outcomes After Lung Cancer Surgery: A 2 × 2 Factorial Randomized Controlled Trial
This study is testing if managing blood pressure and giving dexamethasone during lung cancer surgery can help patients recover better and live longer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1988 (estimated) |
| Ages | 50 Years to 90 Years |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT04209218 on ClinicalTrials.gov |
What this trial studies
This study investigates how intraoperative blood pressure management and the administration of dexamethasone affect outcomes for patients undergoing surgery for non-small cell lung cancer (NSCLC). It focuses on the relationship between blood pressure fluctuations during anesthesia and postoperative complications, as well as the potential benefits of dexamethasone in reducing inflammation and improving recovery. The study aims to determine if tailored blood pressure management can enhance both early and long-term survival rates in these patients. Participants will be monitored for various outcomes related to their surgery and recovery.
Who should consider this trial
Good fit: Ideal candidates are patients aged 50 to 90 with resectable primary non-small cell lung cancer scheduled for radical surgery lasting more than two hours.
Not a fit: Patients with non-resectable lung cancer, recurrent or metastatic disease, or those with uncontrolled hypertension may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved survival rates and reduced complications for lung cancer surgery patients.
How similar studies have performed: Previous studies have shown promising results with individualized blood pressure management in surgical settings, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged \>50 years but \<90 years. * Diagnosed as resectable primary non-small cell lung cancer (stage IA-IIIA) and scheduled for radical surgery with an expected duration of \>2 hours. * Agree to participate in this study and sign the informed consent. Exclusion Criteria: * Clinical examinations suggest non-resectable lung cancer or patients scheduled for a biopsy surgery. * Recurrent or metastatic lung cancer. * History of cancer or complicated with cancer in other organs. * Long-term exposure to glucocorticoids or other immunosuppressant(s) due to autoimmune disease or organ transplantation. * Uncontrolled hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg); or requirement of vasopressors to maintain blood pressure. * Persistent atrial fibrillation, or acute cardiovascular events (acute coronary syndrome, stroke, or congestive heart failure) within 3 months. * Severe hepatic dysfunction (Child-Pugh C) or renal failure (requirement of renal replacement therapy). * Any other circumstances considered unsuitable for study participation by attending physicians or investigators.
Where this trial is running
Beijing, Beijing Municipality
- Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Dong-Xin Wang, MD, PhD — Peking University First Hospital
- Study coordinator: Dong-Xin Wang, MD, PhD
- Email: wangdongxin@hotmail.com
- Phone: 86 (10) 83572784
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.